Literature DB >> 15277491

Role of tumor necrosis factor receptor expression in anterior chamber-associated immune deviation (ACAID) and corneal allograft survival.

Jerry Y Niederkorn1, Elizabeth Mayhew, Jessamee Mellon, Sushma Hegde.   

Abstract

PURPOSE: To determine the role of tumor necrosis factor receptors (TNFRs) in corneal allograft rejection.
METHODS: Corneal epithelial and endothelial cells were examined by flow cytometry for the expression of TNFRI and TNFRII and their susceptibility to TNF-alpha-induced apoptosis. Corneal allografts from normal and TNFRI and TNFRII knockout (KO) C57BL/6 mice were transplanted to BALB/c hosts, and the fate of the allografts was monitored. C57BL/6 spleen cells were injected into the anterior chamber (AC) of BALB/c mice to induce anterior chamber-associated immune deviation (ACAID) and promote corneal allograft survival. The presence of ACAID suppressor cells in corneal allograft recipients was tested using a local adoptive transfer (LAT) assay.
RESULTS: Murine corneal epithelial and endothelial cells expressed TNFRI and TNFRII and were susceptible to TNF-alpha-induced apoptosis, yet corneal allografts from either TNFRI or TNFRII donors did not enjoy a lower incidence of rejection or a prolongation in survival time compared to corneal allografts from normal C57BL/6 donors. Moreover, all 31 of the TNFRII KO corneal grafts were rejected by naïve BALB/c hosts. Rejection of TNFRII KO corneal grafts occurred even though suppressor cells developed in the hosts and inhibited the expression of delayed-type hypersensitivity to donor alloantigens.
CONCLUSIONS: Expression of TNFRII on corneal cells conveys a degree of protection against immune rejection of corneal allografts by a mechanism that is independent of ACAID. Moreover, induction of ACAID before the application of TNFRII KO corneal allografts fails to improve survival and does not replace the TNFRII-dependent protective mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277491     DOI: 10.1167/iovs.04-0144

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Barrier dysfunction of the corneal endothelium in response to TNF-alpha: role of p38 MAP kinase.

Authors:  Mahesh Shivanna; Gangaraju Rajashekhar; Sangly P Srinivas
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-09-24       Impact factor: 4.799

2.  Elevated cAMP opposes (TNF-alpha)-induced loss in the barrier integrity of corneal endothelium.

Authors:  Mahesh Shivanna; Sangly P Srinivas
Journal:  Mol Vis       Date:  2010-09-02       Impact factor: 2.367

3.  Feasibility study of lamellar keratoplasty in a murine model.

Authors:  Ting Huang; Stephen R Planck; James T Rosenbaum; Ellen J Lee
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

4.  Inflammatory cytokine TNF-α promotes corneal endothelium apoptosis via upregulating TIPE2 transcription during corneal graft rejection.

Authors:  Qun Wang; Chao Wei; Li Ma; Xin Wang; Lin Li; Qingjun Zhou; Weiyun Shi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-26       Impact factor: 3.117

Review 5.  Cellular and Molecular Mechanisms of Anterior Chamber-Associated Immune Deviation (ACAID): What We Have Learned from Knockout Mice.

Authors:  Julie Vendomèle; Quentin Khebizi; Sylvain Fisson
Journal:  Front Immunol       Date:  2017-11-30       Impact factor: 7.561

6.  Retinal degeneration in experimental coronavirus retinopathy (ECOR) is associated with increased TNF-alpha, soluble TNFR2 and altered TNF-alpha signaling.

Authors:  Laura C Hooper; Marian S Chin; Barbara Detrick; John J Hooks
Journal:  J Neuroimmunol       Date:  2005-09       Impact factor: 3.478

7.  Effects of ROCK Inhibitors on Apoptosis of Corneal Endothelial Cells in CMV-Positive Posner-Schlossman Syndrome Patients.

Authors:  Nozomi Igarashi; Megumi Honjo; Toshikatsu Kaburaki; Makoto Aihara
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-08-03       Impact factor: 4.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.